Please provide your email address to receive an email when new articles are posted on . Selarsdi is approved for the treatment of plaque psoriasis, psoriatic arthritis in adults, patients aged 6 years ...

The Food and Drug Administration has approved Celltrion's Steqeyma (ustekinumab-stba), a biosimilar to Johnson & Johnson's Stelara (ustekinumab), for subcutaneous injection or intravenous infusion in ...

Medicare and its beneficiaries are paying significantly more for Stelara, Johnson & Johnson’s (NYSE:JNJ) popular biologic drug used to treat autoimmune diseases when obtained through pharmacies rather ...

Sept. 26 -- FRIDAY, Sept. 25 (HealthDay News) -- Stelara (ustekinumab) has been approved by the U.S. Food and Drug Administration for adults with moderate-to-severe plaque psoriasis. The immune system ...

(Reuters) - Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis treatment. The lawsuit, filed ...

Amid patent expirations, litigation and tariff costs, J&J says it expects more growth ahead, fueled in part by its blood ...

Stelara (ustekinumab) is indicated for moderate to severe psoriasis, active psoriatic arthritis, Crohn's disease, and ulcerative colitis. Janssen had previously reached agreements allowing competitors ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved the Stelara biosimilar Yesintek for indications matching the reference product, with a ...

Dong-A-ST's Imuldosa (ustekinumab-srlf/DMB-3115), a biosimilar to Stelara, has won the Food and Drug Administration’s approval. “This FDA approval indicates ...

Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, now available in a 45 mg/0.5 mL single dose vial from Fresenius Kabi. 45 mg/0.5 mL single dose vial provides dosing flexibility for pediatric ...